Insulin Treatment for Gestational Diabetes Mellitus
Abstract
Abstract
Introduction: Gestational diabetes is one of the most common pathologies in pregnancy that can potentially cause other complications, both to the mother and the fetus. This condition is considered a global health problem, with Asia having the highest prevalence.
Methods: This article is a literature review of publications from the past five years (2019–2024) obtained from the NCBI, PubMed, and Science Direct databases. The keywords used include “gestational diabetes,” “insulin therapy,” “types of insulin,” dan “management”.
Results: Insulin remains the gold standard therapy for managing GDM when lifestyle interventions over 1–2 weeks fail to achieve glycemic targets. Various types of insulin, such as human insulin, rapid-acting analogs (lispro, aspart), intermediate-acting insulin (NPH), and basal analogs (detemir, glargine), are considered safe and effective for use during pregnancy
Discussion: The main advantage of insulin is that it does not cross the placenta, thereby avoiding teratogenic risks. Some insulin analogs, such as lispro and detemir, have the advantage of reducing the risk of maternal hypoglycemia and providing more stable glycemic control.
Conclusion: Insulin is the only therapy that does not cross the placenta, and most types do not affect pregnancy and fetuses or neonates.
Keywords: diabetes gestational; insulin; treatment
Pengobatan Insulin untuk Diabetes Mellitus Gestasional
Abstrak
Pendahuluan: Diabetes gestasional merupakan salah satu patologi yang paling umum terjadi pada kehamilan. Penyakit ini berpotensi menimbulkan komplikasi lain, baik pada ibu maupun janin. Kondisi ini dianggap sebagai masalah kesehatan global dan di Asia memiliki prevalensi tertinggi.
Metode: Artikel ini merupakan tinjauan literatur dari publikasi dalam lima tahun terakhir (2019–2024) yang diperoleh dari basis data NCBI, PubMed, dan Science Direct. Kata kunci yang digunakan meliputi “gestational diabetes,” “insulin therapy,” “types of insulin,” dan “management”.
Hasil: Hasil penelitian menunjukkan bahwa insulin tetap menjadi terapi standar emas dalam penatalaksanaan GDM apabila intervensi gaya hidup selama 1 – 2 minggu tidak mampu mencapai target glikemik. Berbagai jenis insulin seperti insulin manusia, analog kerja cepat (lispro, aspart), insulin intermediet (NPH), dan analog basal (detemir, glargine) dinilai aman dan efektif digunakan selama kehamilan.
Diskusi: Keuntungan utama insulin adalah tidak melewati plasenta sehingga menghindari risiko teratogenik. Beberapa jenis insulin analog seperti lispro dan detemir memiliki keunggulan berupa penurunan risiko hipoglikemia maternal dan kontrol glikemik yang lebih stabil.
Kesimpulan: Insulin merupakan satu-satunya terapi yang tidak melewati plasenta dan sebagian besar jenis insulin tidak memiliki efek pada kehamilan dan janin atau neonatus.
Kata kunci: diabetes gestasional; insulin; tatalaksana
Keywords
Full Text:
PDFReferences
Dewi RS, Isfandiari MA, Martini S, Yi-Li C. Prevalence and Risk Factors of Gestational Diabetes Mellitus in Asia: A Review. J Public Health Africa. 2023;14(S2). doi:10.4081/jphia.2023.2583
Mukherjee SM, Dawson A. Diabetes:How to Manage Gestational Diabetes Mellitus. Drugs Context. 2022;11:1-11. doi:10.7573/dic.2021-9-12
Modzelewski R, Stefanowicz-rutkowska MM, Matuszewski W, Bandurskastankiewicz M.Gestational Diabetes Mellitus— Recent Literature Review. Published online 2022:1-14.
Pantea-Stoian A, Adriana SR, Stefan SD. Insulin Therapy in Gestational Diabetes. In: Gestational Diabetes Mellitus – An Overview with Some Recent Advances. Vol 11. IntechOpen; 2020:13. https:// www.intechopen.com/books/advancedbiometric- echnologies/ livenessdetection-in-biometrics
Mazumder T, Akter E, Rahman SM, Islam MT, Talukder MR. Prevalence and Risk Factors of Gestational Diabetes Mellitus in Bangladesh: Findings from Demographic Health Survey 2017– 2018. Int J Environ Res Public Health. 2022;19(5). doi:10.3390/ijerph19052583
Li LJ, Huang L, Tobias DK, Zhang C. Gestational Diabetes Mellitus Among Asians – A Systematic Review From a Population Health Perspective. Front Endocrinol (Lausanne). 2022;13(June). doi:10.3389/fendo.2022.840331
Kwan DP, Susanto R. Prevalence And Characteristics Of Gestational Diabetes Mellitus At X Hospital West Jakarta For The Period Of January 2021 – April 2022. Sci Midwifery. 2022;10(4):27219453. www.midwifery.iocspublisher.orgjournalhomepage:www.midwifery.
iocspublisher.org
Ye W, Luo C, Huang J, Li C, Liu Z, Liu F. Gestational Diabetes Mellitus and Adverse Pregnancy Outcomes: Systematic Review and Meta-analysis. BMJ. Published online 2022. doi:10.1136/bmj-2021-067946
Nayak H, Gadhavi R, Solanki B, et al. Screening for gestational diabetes, Ahmedabad, India. Bull World Health Organ. 2022;100(8):484-490. doi:10.2471/BLT.22.288045
Lende M, Rijhsinghani A. Gestational diabetes: Overview with emphasis on medical management. Int J Environ Res Public Health. 2020;17(24):1-12. doi:10.3390/ijerph17249573
American Diabetes Association. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes-2020. Am Diabetes Assoc. 2020;43(January):S183-S192. doi:10.2337/dc20-S014
Bagias C, Xiarchou A, Saravanan P. Screening, Diagnosis, and Management of GDM: An Update. J Diabetol. 2021;12(5):43. doi:10.4103/jod. jod_101_20
American Diabetes Association. 14. Management of diabetes in pregnancy: Standards of Medical Care in Diabetes – 2021. Diabetes Care. 2021;44(Suppl.1):S200–S210.
Feig DS, Berger H, et al. Diabetes Canada Clinical Practice Guidelines Expert Committee; Diabetes and pregnancy. Can J Diabetes. 2018;42: S255–S282.
Clayton D, Woo V, Yale JF. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. Clinical Practice Guidelines Apr 2013; 37: S69-S71.
Mathiesen ER, Kinsley B, Amiel SA, Heller S, McCance D, Duran S, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart versus human insulin in 322 pregnant women. Diabetes Care 2007;30:771
Lv S, Wang J, Xu Y. Safety of insulin analogs during pregnancy: A meta-analysis. Arch Gynecol Obstet 2015;292:749–56.
American College of Obstetricians and Gynecologists. Gestational Diabetes Mellitus. ACOG Practice Bulletin No. 247. Obstet Gynecol. 2023;141(2):e1–e15.
Mathiesen ER, Kinsley B, Amiel SA, et al. Maternal glycemic control and hypoglycemia in type 1 diabetic pregnancy: A randomized trial of insulin aspart vs human insulin. Diabetes Care. 2007;30(4):771–6.
Feig DS, Berger H, Donovan L, et al. Diabetes and pregnancy. Can J Diabetes. 2018;42 Suppl 1:S255–82
Clayton D, Woo V, Yale JF. Insulin analogs in the management of diabetes mellitus: Practical considerations for use in pregnancy. Can J Diabetes. 2013;37(Suppl 1):S69–71.
Grunberger G, Handelsman Y, Bloomgarden ZT, et al. American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for Developing a Diabetes Mellitus Comprehensive Care Plan—2022. Endocr Pract. 2022;28(1):1–84.
Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med. 2007;167(3):275–83.
Pande RL, Krishnan R, Dunbar A, et al. Access to diabetes medications in lowincome countries: A review. World J Diabetes. 2021;12(6):714–25.
DOI: http://dx.doi.org/10.24198/obgynia.v8i3.823
Refbacks
- There are currently no refbacks.

This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
_CROSREF22.jpg)









